Astellas Pharma

padcev keytruda bladder cancer results, seagen merck bladder cancer combo, padcev keytruda ev-302 trial, padcev keytruda fda approval status, padcev keytruda bladder cancer survival, padcev keytruda bladder cancer safety, padcev keytruda bladder cancer market

Padcev-Keytruda combo cuts death risk in first-line bladder cancer

Anika Sharma

As Seagen readies itself for its impending acquisition by Pfizer, a significant triumph emerges for the company’s cancer drug Padcev, ...

Taysha gene therapy GAN, TSHA-120 FDA feedback, Astellas Taysha gene therapy deal, Taysha pipeline update, GAN gene therapy challenges, Taysha Rett syndrome TSHA-102, Taysha stock price TSHA,

Taysha halts gene therapy for rare nerve disease after FDA and Astellas feedback

Anika Sharma

Astellas has declined the opportunity to exercise an option for an asset from Taysha Gene Therapies. Taysha, facing study design ...

Astellas pharma, drug manufacturing, Manufacturing Facilities, Contract Development and Manufacturing Organization

Astellas to invest $354M in new Irish plant for antibody drugs

Anika Sharma

Astellas is strengthening its significant presence in Ireland with a substantial investment of 330 million euros ($354 million) in a ...

Mycamine, Sandoz, Novartis, Astellas Pharma, antifungal agent, echinocandin

Sandoz Acquires Mycamine, a Top Antifungal Drug, from Astellas

Anika Sharma

In the ever-evolving landscape of medical advancements, Sandoz emerges as a dominant force, orchestrating a strategic move that echoes across ...

IZERVAY: FDA Approves First Drug for Geographic Atrophy

FDA Approves Izervay for Geographic Atrophy

SG Tylor

Source – Astellas Pharma Astellas Pharma has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic ...

Astellas and Eko Health Partner to Integrate Digital Stethoscope into Heart Failure Solution

Astellas and Eko Partner for Heart Failure Digital Therapeutics with Eko CORE 500™ Stethoscope

SG Tylor

Source – Astellas Pharma Astellas has obtained the licensing rights to a smart stethoscope device developed by Eko Health, with ...

Fezolinetant's Phase IIIb Trial Demonstrates Promising Topline Results in Treating Menopause-related Vasomotor Symptoms (VMS)

Fezolinetant’s Phase IIIb Trial Demonstrates Promising Topline Results in Treating Menopause-related Vasomotor Symptoms (VMS)

SG Tylor

Source – Astellas Pharma Astellas Pharma recently announced positive preliminary findings on June 27, 2023, from the Phase IIIb DAYLIGHT ...